Abstract Details

Title Real-World Efficacy and Safety of Inebilizumab in Generalized Myasthenia Gravis

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P9 - Poster Session 9 (5:00 PM-6:00 PM)

Poster/Presentation
Number 9-014

Objective To evaluate the real-world efficacy and safety of inebilizumab in patients with generalized myasthenia gravis (gMG).

Background Autoimmune gMG is characterized by fluctuating muscle weakness driven by pathogenic autoantibodies. Inebilizumab, a humanized monoclonal antibody targeting CD19, induces broad B-cell depletion and may mitigate disease activity by eliminating antibody-secreting cells, which are central to disease pathogenesis.

Design/Methods We retrospectively analyzed five patients with gMG (three acetylcholine receptor antibody-positive and two muscle-specific kinase antibody-positive) who received inebilizumab over a 15-month period. Concomitant glucocorticoids were tapered to a target dose of 5 mg/day. Clinical outcomes—including Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), Myasthenia Gravis Composite (MGC), and MG Quality of Life 15-item scale (MG-QoL15)—were assessed at each visit.

Results Mean score changes from baseline to 15 months were QMG (−5.6), MG-ADL (−4.0), MGC (−6.4), and MG-QoL15 (−5.8). All patients achieved a prednisone dose of ≤5 mg/day by month 15. Serum IgM levels declined below the lower limit of normal in all patients, IgG levels were subnormal in two patients, and IgA levels remained stable. Reported adverse events included pneumonia and herpes zoster.

Conclusions Long-term B cell depletion with inebilizumab demonstrated sustained efficacy in reducing disease activity for generalized MG with controllable immune function impacts,making it a favorable option for gMG patients.

Authors/Disclosures
Chao Zhang, PhD PRESENTER	The institution of Prof. Zhang has received research support from Novartis.
Huining Li, MD	Dr. Li has nothing to disclose.
Dongmei Jia (Tianjin Medical University General Hospital)	No disclosure on file
pan jing	Prof. jing has nothing to disclose.
Ti WU, MD	Dr. WU has nothing to disclose.

��ɫ��

��ɫ��